Skip to main content

8 Result(s)

within Erin Joseph Remove this filter

and

  1. No Access

    Article

    Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice

    c-Myc is commonly activated in many human tumors and is functionally important in cellular proliferation, differentiation, apoptosis and cell cycle progression. The activity of c-Myc requires noncovalent inter...

    Jianxia Guo, Robert A. Parise, Erin Joseph… in Cancer Chemotherapy and Pharmacology (2009)

  2. No Access

    Article

    Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

    Purpose: DB-67 is a silatecan, 7-silyl-modified camptothecin, with enhanced lipophilicity and increased blood stability of the active-lactone ring. The generation of a liposomal formulati...

    William C. Zamboni, Laura L. Jung, Sandra Strychor… in Investigational New Drugs (2008)

  3. No Access

    Article

    Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice

    Cytidine analogues such as cytosine arabinoside, gemcitabine, decitabine, 5-azacytidine, 5-fluoro-2′-deoxycytidine and 5-chloro-2′-deoxycytidine undergo rapid catabolism by cytidine deaminase (CD). 3,4,5,6-tet...

    Jan H. Beumer, Julie L. Eiseman, Robert A. Parise… in Cancer Chemotherapy and Pharmacology (2008)

  4. No Access

    Article

    Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts

    We evaluated the antitumor activity of two different schedules of docetaxel and 9-nitrocamptothecin (9NC) in mice bearing human SKOV-3 ovarian carcinoma xenografts and evaluated the plasma, tissue, and tumor d...

    William C. Zamboni, Sandra Strychor, Erin Joseph… in Cancer Chemotherapy and Pharmacology (2008)

  5. No Access

    Article

    Control-Relevant Modeling of the Antitumor Effects of 9-Nitrocamptothecin in SCID Mice Bearing HT29 Human Colon Xenografts

    The mathematical model structure selected to describe system behavior is at least partially dependent on the proposed use of the model. In this paper, a pharmacokinetic(PK)/pharmacodynamic (PD) model for use i...

    John M. Harrold, Julie L. Eiseman… in Journal of Pharmacokinetics and Pharmacody… (2005)

  6. No Access

    Article

    Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

    17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) is a water-soluble analogue of 17-(allylamino)-17-demethoxygeldanamycin (17AAG), a compound currently in clinical trials. These ...

    Julie L. Eiseman, **g Lan, Theodore F. Lagattuta… in Cancer Chemotherapy and Pharmacology (2005)

  7. No Access

    Article

    Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

    SPI-077 and SPI-077 B103 are formulations of cisplatin encapsulated in pegylated STEALTH liposomes that accumulate in tumors. However, the extent to which active platinum (Pt) is released from the liposome is ...

    William C. Zamboni, Anne C. Gervais… in Cancer Chemotherapy and Pharmacology (2004)

  8. No Access

    Chapter and Conference Paper

    Toward Model-Based Chemotherapy Treatment Design

    Pharmacokinetic models of anticancer compounds are growing in prevalence, and these provide implicitly useful guidance in drug dosing. With the construction of pharmacodynamic models of unperturbed, and treate...

    Robert S. Parker, John M. Harrold… in Advanced Methods of Pharmacokinetic and Ph… (2004)